Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 09:35:50 Source:healthViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:A Canadian serial killer who brought victims to a pig farm is hospitalized after a prison assault
Next:Politically motivated crimes in Germany reached their highest level in 2023 since tracking began
You may also like
- France hits go
- Ober throws 6 solid innings as Twins stop 5
- Clippers facing prospect of no Kawhi Leonard in playoff opener against Luka Doncic and Mavericks
- Rapids use pair of own goals to beat Dallas 2
- US defender John Brooks to leave German club Hoffenheim
- China promoting rapid development of commercial space industry: CNSA
- Zelensky, Stoltenberg agree to hold urgent meeting of Ukraine
- Arturas Karnisovas vows to make changes after the Bulls missed playoffs for 2nd straight season
- Warner holds out IPL hot shot Fraser